The concept of combining tafasitamab with allogeneic effector cell therapy could represent a promising new approach for lymphoma therapy.

**Figures**

1. Tafasitamab in combination with 

2. ADCC assays with lymphoma cell lines and 

3. ADCC assays with lymphoma cell lines and 

4. ADCC assays with leukemia patient samples (CLL) and 

5. ADCC assays with leukemia patient samples (MCL) and 

6. MG4101 and tafasitamab efficacy in a disseminated Ramos xenograft model

**References**


**Disclosures**

J H Her, S Cho, Y Hwang: employment – GC LabCell
R Boxhammer, S Steidl, M Patra, J Schanzer, J Endell: employment – MorphoSys AG
D Pretscher: no disclosures

**Correspondence**

jans.endell@morphosys.com